Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100 and PLX-300, both preclinical orally administrable combination therapies; PLX-200, a repurposed oral small molecule for LSDs; and PLX-400, a preclinical novel gene therapy candidate. Founded in 2014, the company is based in Paramus, New Jersey.